Table 5.
Evaluation of T lymphocyte biomarkers and intratumoral expression of CD34 in prostate adenocarcinoma, benign prostatic hyperplasia, and non-malignant adjacent tissue samples.
| Number | Parameters | Control X ± SD |
PCa X ± SD |
Control X ± SD |
BPH X ± SD |
|---|---|---|---|---|---|
| 1 | CD3+ | 44.00 ± 22.62 | 59.00 ± 22.43 | 44.00 ± 22.62 | 57.70 ± 25.48 |
| p values | 0.386 | 0.499 | |||
| 2 | CD4+ | 66.00 ± 48.08 | 54.68 ± 21.09 | 66.00 ± 48.08 | 66.00 ± 26.11 |
| p values | 0.533 | 0.919 | |||
| 3 | CD8+ | 45.00 ± 28.28 | 31.25 ± 17.55 | 45.00 ± 28.28 | 26.00 ± 14.49 |
| p values | 0.334 | 0.166 | |||
| 4 | CD34+ | 1.50 ± 0.70 ** | 26.12 ± 6.84 ** | 1.50 ± 0.70 | 2.60 ± 1.07 |
| p values | 0.000 | 0.204 | |||
Legend: X, obtained results mean; SD, standard deviation; PCa, prostate adenocarcinoma; BPH, benign prostatic hyperplasia; CD3, total lymphocytes; CD4, T helper lymphocytes; CD8, cytotoxic T lymphocytes; CD34, intratumoral CD34 glycoproteins; ** p ≤ 0.01 represents statistically significant differences between controls and experimental samples made by independent t test.